Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1001521rdf:typepubmed:Citationlld:pubmed
pubmed-article:1001521lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:1001521lifeskim:mentionsumls-concept:C0042232lld:lifeskim
pubmed-article:1001521lifeskim:mentionsumls-concept:C0086045lld:lifeskim
pubmed-article:1001521lifeskim:mentionsumls-concept:C1522570lld:lifeskim
pubmed-article:1001521lifeskim:mentionsumls-concept:C0033554lld:lifeskim
pubmed-article:1001521lifeskim:mentionsumls-concept:C0000782lld:lifeskim
pubmed-article:1001521lifeskim:mentionsumls-concept:C0012471lld:lifeskim
pubmed-article:1001521lifeskim:mentionsumls-concept:C0699733lld:lifeskim
pubmed-article:1001521lifeskim:mentionsumls-concept:C1280519lld:lifeskim
pubmed-article:1001521lifeskim:mentionsumls-concept:C1611588lld:lifeskim
pubmed-article:1001521lifeskim:mentionsumls-concept:C0074517lld:lifeskim
pubmed-article:1001521pubmed:issue12lld:pubmed
pubmed-article:1001521pubmed:dateCreated1977-2-16lld:pubmed
pubmed-article:1001521pubmed:abstractTextThe abortifacient effectiveness of three intravaginal Silastic devices impregnated with 15(S)-15-methyl prostaglandin F2alpha (15(S)-Me-PGF2alpha) methyl ester in concentrations of 0.25%, 0.5%, and 1.0% was investigated. Each concentration was tested in 10 patients with gestations ranging from 8 to 19 weeks. Abortion was successfully induced by prostaglandin alone in 6 patients with the 0.25% device, in 9 patients with the 0.5% device, and all 10 patients treated with the 1.0% device. Additionally, three patients treated with the 0.25% device and one patient treated with the 0.5% device aborted with concomitant, continuous, intravenous oxytocin therapy. The mean abortion time with the 0.25% device was 16.43 hours; with the 0.5% device, 16.49 hours; and with the 1.0% device, 10.18 hours. The peripheral plasma levels of 15(S)-Me-PGF2alpha methyl ester were the most variable with the 0.5% device. The plasma levels of 15(S)-Me-PGF2alpha methyl ester of patients receiving the 0.25% device were similar to the levels of patients receiving the 1.0% device. The intravaginal Silastic device impregnated with 15(S)-Me-PGF2alpha methyl ester appears to be an effective abortifacient, but further study is indicated to determine the most efficient device with the fewest side effects.lld:pubmed
pubmed-article:1001521pubmed:languageenglld:pubmed
pubmed-article:1001521pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1001521pubmed:citationSubsetIMlld:pubmed
pubmed-article:1001521pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1001521pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1001521pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1001521pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1001521pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1001521pubmed:statusMEDLINElld:pubmed
pubmed-article:1001521pubmed:monthDeclld:pubmed
pubmed-article:1001521pubmed:issn0015-0282lld:pubmed
pubmed-article:1001521pubmed:authorpubmed-author:LauersenN HNHlld:pubmed
pubmed-article:1001521pubmed:authorpubmed-author:WilsonK HKHlld:pubmed
pubmed-article:1001521pubmed:issnTypePrintlld:pubmed
pubmed-article:1001521pubmed:volume27lld:pubmed
pubmed-article:1001521pubmed:ownerNLMlld:pubmed
pubmed-article:1001521pubmed:authorsCompleteYlld:pubmed
pubmed-article:1001521pubmed:pagination1366-73lld:pubmed
pubmed-article:1001521pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:meshHeadingpubmed-meshheading:1001521-...lld:pubmed
pubmed-article:1001521pubmed:year1976lld:pubmed
pubmed-article:1001521pubmed:articleTitleThe abortifacient effectiveness and plasma prostaglandin concentrations with 15(S)-15-methyl prostaglandin F2alpha methyl ester-containing vaginal silastic devices.lld:pubmed
pubmed-article:1001521pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1001521lld:pubmed